BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state: Liver Cancer in the United States. CA: A Cancer Journal for Clinicians 2017;67:273-89. [DOI: 10.3322/caac.21402] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 16.2] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Qian Y, Wu M, Cong W. Liver Resection Is Justified in Patients with BCLC Intermediate Stage Hepatocellular Carcinoma without Microvascular Invasion. J Gastrointest Surg 2020;24:2737-47. [DOI: 10.1007/s11605-019-04251-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
2 Ma J, Hong Y, Zheng N, Xie G, Lyu Y, Gu Y, Xi C, Chen L, Wu G, Li Y, Tao X, Zhong J, Huang Z, Wu W, Yuan L, Lin M, Lu X, Zhang W, Jia W, Sheng L, Li H. Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specifically. Gut Microbes 2020;11:1450-74. [PMID: 32515683 DOI: 10.1080/19490976.2020.1763770] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
3 Hughey CC, James FD, Wang Z, Goelzer M, Wasserman DH. Dysregulated transmethylation leading to hepatocellular carcinoma compromises redox homeostasis and glucose formation. Mol Metab 2019;23:1-13. [PMID: 30850319 DOI: 10.1016/j.molmet.2019.02.006] [Reference Citation Analysis]
4 Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38:4317-4345. [PMID: 33197225 DOI: 10.1200/jco.20.02672] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 15.0] [Reference Citation Analysis]
5 Brown HE, Dennis LK, Lauro P, Jain P, Pelley E, Oren E. Emerging Evidence for Infectious Causes of Cancer in the United States. Epidemiol Rev 2019;41:82-96. [PMID: 32294189 DOI: 10.1093/epirev/mxz003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Islami F, Siegel RL, Jemal A. The changing landscape of cancer in the USA — opportunities for advancing prevention and treatment. Nat Rev Clin Oncol 2020;17:631-49. [DOI: 10.1038/s41571-020-0378-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
7 Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, Flanders WD, Brawley OW, Gapstur SM, Jemal A. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68:31-54. [PMID: 29160902 DOI: 10.3322/caac.21440] [Cited by in Crossref: 361] [Cited by in F6Publishing: 318] [Article Influence: 72.2] [Reference Citation Analysis]
8 Wang J, Zhang Y, Liu L, Cui Z, Shi R, Hou J, Liu Z, Yang L, Wang L, Li Y. NFAT2 overexpression suppresses the malignancy of hepatocellular carcinoma through inducing Egr2 expression. BMC Cancer 2020;20:966. [PMID: 33023539 DOI: 10.1186/s12885-020-07474-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zheng Y, Zhang X, Lu J, Liu S, Qian Y. Association between socioeconomic status and survival in patients with hepatocellular carcinoma. Cancer Med 2021;10:7347-59. [PMID: 34414679 DOI: 10.1002/cam4.4223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Zhang Z, Tang H, Chen P, Xie H, Tao Y. Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. Signal Transduct Target Ther 2019;4:41. [PMID: 31637019 DOI: 10.1038/s41392-019-0074-5] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
11 Sun YD, Zhang H, Chen YQ, Wu CX, Chen ML, Xu HR, Wang S, Liu JZ, Han JJ. Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1. BMC Cancer 2021;21:1063. [PMID: 34583662 DOI: 10.1186/s12885-021-08783-8] [Reference Citation Analysis]
12 Zou R, Xiao S, Shi Z, Ke Y, Tang H, Wu T, Guo Z, Ni F, Li W, Wang L. Identification of metabolism-associated pathways and genes involved in male and female liver cancer patients. Journal of Theoretical Biology 2019;480:218-28. [DOI: 10.1016/j.jtbi.2019.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Dar AR, McKillop I, Vickress J, Lock M, Yartsev S. Prognostic Significance of Tumor Location for Liver Cancer Radiotherapy. Cureus 2018;10:e3714. [PMID: 30788203 DOI: 10.7759/cureus.3714] [Reference Citation Analysis]
14 Jimenez H, Wang M, Zimmerman JW, Pennison MJ, Sharma S, Surratt T, Xu ZX, Brezovich I, Absher D, Myers RM, DeYoung B, Caudell DL, Chen D, Lo HW, Lin HK, Godwin DW, Olivier M, Ghanekar A, Chen K, Miller LD, Gong Y, Capstick M, D'Agostino RB Jr, Munden R, Merle P, Barbault A, Blackstock AW, Bonkovsky HL, Yang GY, Jin G, Liu L, Zhang W, Watabe K, Blackman CF, Pasche BC. Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 T-type voltage-gated calcium channels and Ca2+ influx. EBioMedicine 2019;44:209-24. [PMID: 31160272 DOI: 10.1016/j.ebiom.2019.05.034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
15 Zhang W, Luo P. MicroRNA-29c restores cisplatin sensitivity in liver cancer through direct inhibition of sirtuin 1 expression. Oncol Lett 2018;16:1543-50. [PMID: 30008835 DOI: 10.3892/ol.2018.8801] [Reference Citation Analysis]
16 Hai Y, Savsani E, Chong W, Eisenbrey J, Lyshchik A. Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:5162-79. [PMID: 34410432 DOI: 10.1007/s00261-021-03248-9] [Reference Citation Analysis]
17 Sivaram S, Perkins S, He M, Ginsburg E, Dominguez G, Vedham V, Katz F, Parascandola M, Bogler O, Gopal S. Building Capacity for Global Cancer Research: Existing Opportunities and Future Directions. J Cancer Educ 2021;36:5-24. [PMID: 34273100 DOI: 10.1007/s13187-021-02043-w] [Reference Citation Analysis]
18 Ye W, Siwko S, Tsai RYL. Sex and Race-Related DNA Methylation Changes in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:3820. [PMID: 33917049 DOI: 10.3390/ijms22083820] [Reference Citation Analysis]
19 Tenner L, Melhado TV, Bobadilla R, Turner BJ, Morgan R. The Cost of Cure: Barriers to Access for Hepatitis C Virus Treatment in South Texas. J Oncol Pract 2019;15:61-3. [PMID: 30668219 DOI: 10.1200/JOP.18.00525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
20 He J, Li G, Liu X, Ma L, Zhang P, Zhang J, Zheng S, Wang J, Liu J. Diagnostic and Prognostic Values of MANF Expression in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:1936385. [PMID: 32382531 DOI: 10.1155/2020/1936385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Khamis ZI, Pang X, Cui Z, Sang QA, Zhang J. Cytochrome P450-2D6: A novel biomarker in liver cancer health disparity. PLoS One 2021;16:e0257072. [PMID: 34597305 DOI: 10.1371/journal.pone.0257072] [Reference Citation Analysis]
22 Zhang Z, Chen P, Xie H, Cao P. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis. Cancer Med 2020;9:1349-64. [PMID: 31876977 DOI: 10.1002/cam4.2799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
23 Tu J, Zhao Z, Xu M, Lu X, Chang L, Ji J. NEAT1 upregulates TGF‐β1 to induce hepatocellular carcinoma progression by sponging hsa‐mir‐139‐5p. J Cell Physiol 2018;233:8578-87. [DOI: 10.1002/jcp.26524] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
24 Chen Z, Lu X, Koral K. The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:1017-24. [PMID: 32762583 DOI: 10.1080/17474124.2020.1807939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Wu J, Yang S, Xu K, Ding C, Zhou Y, Fu X, Li Y, Deng M, Wang C, Liu X, Li L. Patterns and Trends of Liver Cancer Incidence Rates in Eastern and Southeastern Asian Countries (1983-2007) and Predictions to 2030. Gastroenterology 2018;154:1719-1728.e5. [PMID: 29549041 DOI: 10.1053/j.gastro.2018.01.033] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
26 Muhimpundu S, Conway RBN, Warren Andersen S, Lipworth L, Steinwandel MD, Blot WJ, Shu XO, Sudenga SL. Racial Differences in Hepatocellular Carcinoma Incidence and Risk Factors among a Low Socioeconomic Population. Cancers (Basel) 2021;13:3710. [PMID: 34359611 DOI: 10.3390/cancers13153710] [Reference Citation Analysis]
27 Zheng L, Li C, Huang X, Lin X, Lin W, Yang F, Chen T. Thermosensitive hydrogels for sustained-release of sorafenib and selenium nanoparticles for localized synergistic chemoradiotherapy. Biomaterials 2019;216:119220. [DOI: 10.1016/j.biomaterials.2019.05.031] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
28 Rhoades DA, Farley J, Schwartz SM, Malloy KM, Wang W, Best LG, Zhang Y, Ali T, Yeh F, Rhoades ER, Lee E, Howard BV. Cancer mortality in a population-based cohort of American Indians - The strong heart study. Cancer Epidemiol 2021;74:101978. [PMID: 34293639 DOI: 10.1016/j.canep.2021.101978] [Reference Citation Analysis]
29 Rao B, Ren T, Wang X, Wang H, Zou Y, Sun Y, Liu S, Ren Z, Yu Z. Dysbiosis in the Human Microbiome of Cholangiocarcinoma. Front Physiol 2021;12:715536. [PMID: 34867436 DOI: 10.3389/fphys.2021.715536] [Reference Citation Analysis]
30 Beck JR, Cabral F, Rasineni K, Casey CA, Harris EN, Stains CI. A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease. Biochemistry 2019;58:3911-7. [PMID: 31433166 DOI: 10.1021/acs.biochem.9b00547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Shawky E, Takla SS, Hammoda HM, Darwish FA. Evaluation of the influence of green extraction solvents on the cytotoxic activities of Crinum (Amaryllidaeae) alkaloid extracts using in-vitro-in-silico approach. J Ethnopharmacol 2018;227:139-49. [PMID: 30179713 DOI: 10.1016/j.jep.2018.08.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
32 Valean S, Chira R, Dumitrascu D. Epidemiological trends in digestive cancers in Romania, 1955-2012, compared to alcohol consumption. Correlation or coincidence? Clujul Med 2018;91:376-86. [PMID: 30564012 DOI: 10.15386/cjmed-1067] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Hasanzad M, Sarhangi N, Aghaei Meybodi HR, Nikfar S, Khatami F, Larijani B. Precision Medicine in Non Communicable Diseases. Int J Mol Cell Med 2019;8:1-18. [PMID: 32351905 DOI: 10.22088/IJMCM.BUMS.8.2.1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Wang J, Li X. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis. Eur J Gastroenterol Hepatol 2021;33:1603-9. [PMID: 33405428 DOI: 10.1097/MEG.0000000000002040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Li C, Fu Q, Cai J, Mei H, Shangguan W. Effects of propofol on the proliferation and migration of liver cancer cells. Exp Ther Med 2021;22:733. [PMID: 34055050 DOI: 10.3892/etm.2021.10165] [Reference Citation Analysis]
36 Wang H, Yu H, Qian YW, Cao ZY, Wu MC, Cong WM. Postoperative adjuvant transcatheter arterial chemoembolization improves the prognosis of patients with huge hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021;20:232-9. [PMID: 33455865 DOI: 10.1016/j.hbpd.2020.12.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Sun JR, Kong CF, Xiao KM, Yang JL, Qu XK, Sun JH. Integrated Analysis of lncRNA-Mediated ceRNA Network Reveals a Prognostic Signature for Hepatocellular Carcinoma. Front Genet 2020;11:602542. [PMID: 33381151 DOI: 10.3389/fgene.2020.602542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Sun CY, Zhu Y, Li XF, Tang LP, Su ZQ, Wang XQ, Li CY, Yang HM, Zheng GJ, Feng B. Norcantharidin alone or in combination with crizotinib induces autophagic cell death in hepatocellular carcinoma by repressing c-Met-mTOR signaling. Oncotarget. 2017;8:114945-114955. [PMID: 29383132 DOI: 10.18632/oncotarget.22935] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
39 Liu K, Tian T, Zheng Y, Zhou L, Dai C, Wang M, Lin S, Deng Y, Hao Q, Zhai Z, Dai Z. Scutellarin inhibits proliferation and invasion of hepatocellular carcinoma cells via down-regulation of JAK2/STAT3 pathway. J Cell Mol Med. 2019;23:3040-3044. [PMID: 30697962 DOI: 10.1111/jcmm.14169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
40 Mak D, Sengayi M, Chen WC, Babb de Villiers C, Singh E, Kramvis A. Liver cancer mortality trends in South Africa: 1999-2015.BMC Cancer. 2018;18:798. [PMID: 30086727 DOI: 10.1186/s12885-018-4695-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
41 Wu X, Wang Q, Lu Y, Zhang J, Yin H, Yi Y. Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Sci Rep 2021;11:6069. [PMID: 33727662 DOI: 10.1038/s41598-021-85688-3] [Reference Citation Analysis]
42 Li YM, Liu ZY, Wang JC, Yu JM, Li ZC, Yang HJ, Tang J, Chen ZN. Receptor-Interacting Protein Kinase 3 Deficiency Recruits Myeloid-Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C-X-C Motif) Ligand 1-Chemokine (C-X-C Motif) Receptor 2 Axis. Hepatology 2019;70:1564-81. [PMID: 31021443 DOI: 10.1002/hep.30676] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
43 Che YQ, Zhang Y, Li HB, Shen D, Cui W. Serum KLKB1 as a Potential Prognostic Biomarker for Hepatocellular Carcinoma Based on Data-Independent Acquisition and Parallel Reaction Monitoring. J Hepatocell Carcinoma 2021;8:1241-52. [PMID: 34676182 DOI: 10.2147/JHC.S325629] [Reference Citation Analysis]
44 Kamath GR, Taioli E, N Egorova N, Llovet JM, Perumalswami PV, Weiss JJ, Schwartz M, Ewala S, Bickell NA. Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors. Front Oncol 2018;8:220. [PMID: 29963497 DOI: 10.3389/fonc.2018.00220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Xu K, Watanabe-Galloway S, Rochling FA, Farazi PA, Monirul Islam KM, Wang H, Luo J. Surgical Delay Is Associated with Improved Survival in Hepatocellular Carcinoma: Results of the National Cancer Database. J Gastrointest Surg 2019;23:933-43. [PMID: 30328070 DOI: 10.1007/s11605-018-3925-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
46 Yu W, Dai Y. lncRNA LOXL1-AS1 promotes liver cancer cell proliferation and migration by regulating the miR-377-3p/NFIB axis. Oncol Lett 2021;22:624. [PMID: 34267816 DOI: 10.3892/ol.2021.12885] [Reference Citation Analysis]
47 Zheng R, Qu C, Zhang S, Zeng H, Sun K, Gu X, Xia C, Yang Z, Li H, Wei W, Chen W, He J. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin J Cancer Res. 2018;30:571-579. [PMID: 30700925 DOI: 10.21147/j.issn.1000-9604.2018.06.01] [Cited by in Crossref: 62] [Cited by in F6Publishing: 80] [Article Influence: 15.5] [Reference Citation Analysis]
48 Salvatore M, Jeon J, Meza R. Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992-2016. Cancer Causes Control 2019;30:1377-88. [PMID: 31606852 DOI: 10.1007/s10552-019-01237-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura T, Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. J Gastroenterol 2019;54:367-76. [PMID: 30498904 DOI: 10.1007/s00535-018-1532-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 14.5] [Reference Citation Analysis]
50 Yang B, Liu JB, So SK, Han SS, Wang SS, Hertz A, Shariff-Marco S, Lin Gomez S, Rosenberg PS, Nguyen MH, Hsing AW. Disparities in hepatocellular carcinoma incidence by race/ethnicity and geographic area in California: Implications for prevention. Cancer 2018;124:3551-9. [PMID: 30113700 DOI: 10.1002/cncr.31598] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
51 Yang Y, Vankayalapati H, Tang M, Zheng Y, Li Y, Ma C, Lai K. Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents. Molecules 2020;25:E645. [PMID: 32028604 DOI: 10.3390/molecules25030645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
52 Zheng T, Zhu C, Bassig BA, Liu S, Buka S, Zhang X, Truong A, Oh J, Fulton J, Dai M, Li N, Shi K, Qian Z, Boyle P. The long-term rapid increase in incidence of adenocarcinoma of the kidney in the USA, especially among younger ages. Int J Epidemiol 2019;48:1886-96. [PMID: 31317187 DOI: 10.1093/ije/dyz136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Shiels MS, O'Brien TR. Declining US Hepatocellular Carcinoma Rates, 2014-2017. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00112-9. [PMID: 33549870 DOI: 10.1016/j.cgh.2021.02.011] [Reference Citation Analysis]
54 Taki S, Ardestani MS. Novel nanosized AS1411-chitosan-BODIPY conjugate for molecular fluorescent imaging. Int J Nanomedicine 2019;14:3543-55. [PMID: 31190811 DOI: 10.2147/IJN.S202561] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Quan H, Li B, Yang J. MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling. Biomed Pharmacother 2018;107:754-62. [PMID: 30142536 DOI: 10.1016/j.biopha.2018.07.150] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
56 Ma J, Siegel RL, Islami F, Jemal A. Temporal trends in liver cancer mortality by educational attainment in the United States, 2000-2015. Cancer 2019;125:2089-98. [PMID: 30957228 DOI: 10.1002/cncr.32023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
57 Liu B, Bai C. Regulatory Mechanisms of Coicis Semen on Bionetwork of Liver Cancer Based on Network Pharmacology. Biomed Res Int 2020;2020:5860704. [PMID: 33294448 DOI: 10.1155/2020/5860704] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Lee AW, Jacobs W, Chan E, Nguyen B, Hua DN, Ho JN, Yuen P, Van Nguyen T. Insight into hepatitis B prevalence and risk factors among Vietnamese Americans: a cross-sectional analysis of data from a community-based screening program. BMJ Open 2019;9:e029616. [PMID: 31455706 DOI: 10.1136/bmjopen-2019-029616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
59 Endeshaw M, Hallowell BD, Razzaghi H, Senkomago V, McKenna MT, Saraiya M. Trends in liver cancer mortality in the United States: Dual burden among foreign- and US-born persons. Cancer 2019;125:726-34. [PMID: 30480828 DOI: 10.1002/cncr.31869] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
60 Smith JW, Kroker-Lobos MF, Lazo M, Rivera-Andrade A, Egner PA, Wedemeyer H, Torres O, Freedman ND, McGlynn KA, Guallar E, Groopman JD, Ramirez-Zea M. Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. PLoS One 2017;12:e0189255. [PMID: 29236788 DOI: 10.1371/journal.pone.0189255] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
61 Sheng X, Ji Y, Ren GP, Lu CL, Yun JP, Chen LH, Meng B, Qu LJ, Duan GJ, Sun Q, Ye XQ, Li SS, Yang J, Liao B, Wang ZB, Zhou JH, Sun Y, Qiu XS, Wang L, Li ZS, Chen J, Xia CY, He S, Li CY, Xu EW, Geng JS, Pan C, Kuang D, Qin R, Guan HW, Wang ZD, Li LX, Zhang X, Wang H, Zhao Q, Wei B, Zhang WJ, Ling SP, Du X, Cong WM; Liver Cancer Pathology Group of China (LCPGC). A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC. Hepatol Int 2020;14:1034-47. [PMID: 33369707 DOI: 10.1007/s12072-020-10111-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
62 Varghese RS, Barefoot ME, Jain S, Chen Y, Zhang Y, Alley A, Kroemer AH, Tadesse MG, Kumar D, Sherif ZA, Ressom HW. Integrative Analysis of DNA Methylation and microRNA Expression Reveals Mechanisms of Racial Heterogeneity in Hepatocellular Carcinoma. Front Genet 2021;12:708326. [PMID: 34557219 DOI: 10.3389/fgene.2021.708326] [Reference Citation Analysis]
63 Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:171. [PMID: 32185125 DOI: 10.3389/fonc.2020.00171] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
64 Xia S, Wu J, Zhou W, Zhang M, Zhao K, Tian D, Liu J, Liao J. HRC promotes anoikis resistance and metastasis by suppressing endoplasmic reticulum stress in hepatocellular carcinoma. Int J Med Sci 2021;18:3112-24. [PMID: 34400882 DOI: 10.7150/ijms.60610] [Reference Citation Analysis]
65 Ortiz AG, Wiese D, Sorice KA, Nguyen M, González ET, Henry KA, Lynch SM. Liver Cancer Incidence and Area-Level Geographic Disparities in Pennsylvania-A Geo-Additive Approach. Int J Environ Res Public Health 2020;17:E7526. [PMID: 33081168 DOI: 10.3390/ijerph17207526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younossi ZM. The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. Hepatol Commun 2021;5:749-59. [PMID: 34027266 DOI: 10.1002/hep4.1673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Chang CW, Lo JF, Wang XW. Roles of mitochondria in liver cancer stem cells. Differentiation 2019;107:35-41. [PMID: 31176254 DOI: 10.1016/j.diff.2019.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
68 Thomas ML, Marcato P. Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum. Cancers (Basel) 2018;10:E101. [PMID: 29614786 DOI: 10.3390/cancers10040101] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
69 Stewart SL, Dang JH, Török NJ, Chen MS Jr. Patterns and co-occurrence of risk factors for hepatocellular carcinoma in four Asian American communities: a cross-sectional study. BMJ Open 2019;9:e026409. [PMID: 31256022 DOI: 10.1136/bmjopen-2018-026409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
70 Dauki AM, Blachly JS, Kautto EA, Ezzat S, Abdel-Rahman MH, Coss CC. Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression. Cancer Res 2020;80:561-75. [PMID: 31685543 DOI: 10.1158/0008-5472.CAN-19-1117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
71 Jensen T, Wieland A, Cree-Green M, Nadeau K, Sullivan S. Clinical workup of fatty liver for the primary care provider. Postgrad Med 2019;131:19-30. [PMID: 30496690 DOI: 10.1080/00325481.2019.1546532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Shiels MS, O'Brien TR. Recent Decline in Hepatocellular Carcinoma Rates in the United States. Gastroenterology. 2020;158:1503-1505.e2. [PMID: 31962125 DOI: 10.1053/j.gastro.2019.12.030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
73 Cunningham SA, Yu R, Shih T, Giordano S, McNeill LH, Rechis R, Peterson SK, Cinciripini P, Foxhall L, Hawk E, Shete S. Cancer-Related Risk Perceptions and Beliefs in Texas: Findings from a 2018 Population-Level Survey. Cancer Epidemiol Biomarkers Prev 2019;28:486-94. [PMID: 30700446 DOI: 10.1158/1055-9965.EPI-18-0846] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
74 Paredes AZ, Guzman-pruneda FA, Abdel-misih S, Hays J, Dillhoff ME, Pawlik TM, Cloyd JM. Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis. Journal of Surgical Research 2019;241:31-9. [DOI: 10.1016/j.jss.2019.03.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
75 Sherif ZA, Nouraie SM, Lee E, Aduli F, Brim H, Ashktorab H. Trends in the Incidence of Hepatocellular Carcinoma in Washington DC: A Single Institutional Cohort Study (1959-2013). J Natl Med Assoc 2021;113:396-404. [PMID: 33648723 DOI: 10.1016/j.jnma.2021.02.001] [Reference Citation Analysis]
76 E C, Li C, Li H, Yang J. Silencing of a novel lncRNA LOC105369748 suppresses the progression of hepatocellular carcinoma by sponging miR-5095 from MBD2. J Cell Physiol 2019;234:18504-12. [PMID: 30912130 DOI: 10.1002/jcp.28486] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
77 Wu J, Liu L, Jin H, Li Q, Wang S, Peng B. LncSNHG3/miR-139-5p/BMI1 axis regulates proliferation, migration, and invasion in hepatocellular carcinoma. Onco Targets Ther 2019;12:6623-38. [PMID: 31692508 DOI: 10.2147/OTT.S196630] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
78 Li JR, Malhotra A, Bi J. Potential of Ablation Therapy during Hepatocellular Carcinoma. Nutr Cancer 2019;71:881-5. [PMID: 30558451 DOI: 10.1080/01635581.2018.1531137] [Reference Citation Analysis]
79 Lee CM, Lee J, Jang SN, Shon JC, Wu Z, Park K, Liu KH, Park SH. 6,8-Diprenylorobol Induces Apoptosis in Human Hepatocellular Carcinoma Cells via Activation of FOXO3 and Inhibition of CYP2J2. Oxid Med Cell Longev 2020;2020:8887251. [PMID: 33312341 DOI: 10.1155/2020/8887251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Pujol F, Jaspe RC, Loureiro CL, Chemin I. Hepatitis B virus American genotypes: Pathogenic variants ? Clin Res Hepatol Gastroenterol 2020;44:825-35. [PMID: 32553521 DOI: 10.1016/j.clinre.2020.04.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
81 Liu LZ, Zhang Z, Zheng BH, Shi Y, Duan M, Ma LJ, Wang ZC, Dong LQ, Dong PP, Shi JY, Zhang S, Ding ZB, Ke AW, Cao Y, Zhang XM, Xi R, Zhou J, Fan J, Wang XY, Gao Q. CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma. Hepatology. 2019;69:143-159. [PMID: 30070719 DOI: 10.1002/hep.30134] [Cited by in Crossref: 43] [Cited by in F6Publishing: 51] [Article Influence: 10.8] [Reference Citation Analysis]
82 Xia S, Wu J, Zhou W, Zhang M, Zhao K, Liu J, Tian D, Liao J. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. Cell Death Dis 2021;12:570. [PMID: 34108444 DOI: 10.1038/s41419-021-03853-y] [Reference Citation Analysis]
83 Siegel RL, Jemal A, Wender RC, Gansler T, Ma J, Brawley OW. An assessment of progress in cancer control. CA Cancer J Clin. 2018;68:329-339. [PMID: 30191964 DOI: 10.3322/caac.21460] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 17.5] [Reference Citation Analysis]
84 Miethe C, Zamora M, Torres L, Raign KG, Groll CJ, Price RS. Characterizing the differential physiological effects of adipocytokines visfatin and resistin in liver cancer cells. Horm Mol Biol Clin Investig 2019;38:/j/hmbci. [PMID: 30917102 DOI: 10.1515/hmbci-2018-0068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
85 Franco RA, Fan Y, Jarosek S, Bae S, Galbraith J. Racial and Geographic Disparities in Hepatocellular Carcinoma Outcomes. Am J Prev Med 2018;55:S40-8. [PMID: 30670200 DOI: 10.1016/j.amepre.2018.05.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
86 Yang J, Zhao L, Zhang N, Du Z, Li Y, Li X, Zhao D, Wang J. Cancer death and potential years of life lost in Feicheng City, China: Trends from 2013 to 2018. Medicine (Baltimore) 2021;100:e27370. [PMID: 34596152 DOI: 10.1097/MD.0000000000027370] [Reference Citation Analysis]
87 Feng J, He Y, Wan J, Chen Z. Pulmonary metastases in newly diagnosed hepatocellular carcinoma: a population-based retrospective study. HPB (Oxford) 2020;22:1295-304. [PMID: 31892468 DOI: 10.1016/j.hpb.2019.12.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Adler Jaffe S, Myers O, Meisner ALW, Wiggins CL, Hill DA, McDougall JA. Relationship between Insurance Type at Diagnosis and Hepatocellular Carcinoma Survival. Cancer Epidemiol Biomarkers Prev 2020;29:300-7. [PMID: 31796525 DOI: 10.1158/1055-9965.EPI-19-0902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Lewis DR, Chen HS, Cockburn MG, Wu XC, Stroup AM, Midthune DN, Zou Z, Krapcho MF, Miller DG, Feuer EJ. Early estimates of cancer incidence for 2015: Expanding to include estimates for white and black races. Cancer 2018;124:2192-204. [PMID: 29509274 DOI: 10.1002/cncr.31315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
90 Wu G, Wu J, Pan X, Liu B, Yao Z, Guo Y, Shi X, Ding Y. Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients. Cancer Med. 2019;8:6614-6623. [PMID: 31517445 DOI: 10.1002/cam4.2549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]